Open Actively Recruiting

FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma

About

Brief Summary

This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.

Primary Purpose
Diagnostic
Study Type
Interventional
Phase
N/A

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
99 Years

Inclusion Criteria:

  • Patients with histologically proven high grade glioma
  • Intention to start therapy

Exclusion Criteria:

  • Severe psychiatric illness
  • Inability to give written consent
  • Breast feeding / pregnancy

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
15-000409
Category
Molecular & Medical Pharmacology
Oncology
Contact
JEREMIE CALAIS
Location
  • UCLA Westwood
For Providers
NCT No.
NCT02902757
For detailed technical eligibility, visit ClinicalTrials.gov.